NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

Authors
Category Primary study
JournalANNALS OF ONCOLOGY
Year 2022
This article has no abstract
Epistemonikos ID: 1d10c74d55484412ee318d5babb389a24eb602da
First added on: Feb 15, 2025